Navigation Links
Drop in Breast Cancer Rates Due to Drop in HRT Use
Date:2/4/2009

Researchers say first two years of combined hormone therapy a 'safe' period

WEDNESDAY, Feb. 4 (HealthDay News) -- A new analysis shows that the drop in breast cancer cases that began in 2003 is indeed due to women stopping hormone replacement therapy (HRT) after a large, U.S. study showed surprisingly higher rates of heart problems and breast cancer among users of some kinds of HRT.

Some experts have suggested such a theory explains the trend, while others have said it might be related to changes in mammography use.

"If you stop hormones, the risk of breast cancer [associated with hormone use] rapidly declines," said Dr. Rowan Chlebowski, a medical oncologist at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of the analysis in the Feb. 5 issue of the New England Journal of Medicine.

Based on that analysis and another recent review, the researchers also suggested that the "safe" period for combined use of progestin and estrogen to relieve postmenopausal symptoms was probably about two years, not the approximately five years researchers have discussed previously.

To get to the root of the drop in breast cancer cases, Chlebowski and his colleagues looked at data from the Women's Health Initiative (WHI) clinical trial (more than 15,000 women were assigned to either a placebo or HRT) and an observational study in which more than 25,000 women were on HRT, and more than 16,000 were not.

The part of the WHI that looked at combined hormone therapy was halted in 2002, as soon as researchers saw surprisingly higher rates of heart problems and breast cancer in women assigned to take the combined HRT (but not estrogen alone).

When Chlebowski's group looked in more detail and at shorter intervals for the effects of HRT, they found that during the initial two years, the HRT group participating in the clinical trial had fewer breast cancer diagnoses than the placebo group. However, the number of breast cancer cases in that group increased over the 5.6-year study period. The risk decreased rapidly in both groups after they stopped the pills, even though both groups had mammograms with similar frequency.

That fact weakens the argument that the drop in breast cancer cases was due to fewer women getting mammograms, he noted.

"There was a rapid decline in breast cancer incidence after stopping hormones, while mammography use didn't change between the groups," Chlebowski explained.

For instance, in the observational study, the incidence of breast cancer was about two times as high in the group on hormones as in the placebo group, but the difference faded about two years later, as women discontinued the hormones.

The bad news is that women who continue the combined HRT for about five years are at increased risk for breast cancer, the new analysis suggested.

"A woman who continues combined hormone therapy after about five years would double her personal annual risk of breast cancer," said Dr. Marcia Stefanick, a professor of medicine at Stanford University School of Medicine and a co-author of the analysis. That risk increases even when adjustments were made for age, which boosts risk on its own, she said. What happens with risk after that five years of use is not known, she said.

Another study, published online earlier this week in the journal Cancer, also finds that two years may be a "safe" period for the use of combined HRT. Eugenia Calle, former vice president of epidemiology for the American Cancer Society, and her colleagues looked at about 68,000 women who were cancer-free at the study's start in 1992, evaluating their hormone use and risk of getting breast cancer, and following them until mid-2005.

They found that the risk of breast cancer increased substantially after three years of using HRT -- for lobular cancer, the therapy doubled the risk at three years -- but there was no increased risk for those who used it for less than two years. However, Chlebowski said cancers may simply be harder to detect on mammograms during initial hormone use.

So what's the best advice on hormone use?

"Our paper suggests after starting estrogen plus progestin, you probably have two or three years where your risk isn't elevated," Calle told HealthDay. "And after that, your risk is elevated."

The new findings "add to a large accumulating volume of data," said Dr. Joann Elmore, a professor of medicine at the University of Washington, in Seattle. Overall, the data suggest that "the benefit of hormone therapy is less than we had hoped for, and there are risks that need to be considered." Each woman needs to weigh the risks and benefits, taking into account the severity of her symptoms, she added.

Chlebowski suggested that women consider stopping the hormones after two to five years and see if symptoms persist. "A truly safe interval can't be defined," he said.

More information

To learn more about HRT, visit the American Cancer Society.



SOURCES: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, Calif.; Joann G. Elmore, M.D., M.P.H., professor, medicine, University of Washington, Seattle; Marcia Stefanick, M.D., Ph.D., professor, medicine, Stanford University School of Medicine, Stanford, Calif.; Eugenia Calle, former vice president, epidemiology, American Cancer Society, Atlanta; Feb. 5, 2009, New England Journal of Medicine; Feb. 2, 2009, Cancer, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U-M Study: 19% of Breast Cancer Patients Dont Receive Recommended Radiation After Mastectomy
2. 19 percent of breast cancer patients dont receive recommended radiation after mastectomy
3. 19 percent of breast cancer patients don’t receive recommended radiation after mastectomy
4. Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens
5. NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
6. 11-gauge needle better than 14-gauge in breast biopsy
7. Workforce shortages in mammography could threaten early detection rates for breast cancer
8. Radiologists overestimate their overall risk of malpractice lawsuits in breast imaging
9. PET/CT may improve prognosis for patients with inflammatory breast cancer
10. Smithfield Foods Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution
11. Automated screening process may eventually reduce additional breast cancer surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drop in Breast Cancer Rates Due to Drop in HRT Use
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of Buzzies ... stress and anxiety. , “Buzzies change the way we interact with stress and ... , Since its launch date in December 2016, The TouchPoint Solution has sold more ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... 23, 2017 , ... It’s that time of year again! Time to think ... summer internships , which can be frustrating when they don’t even know how to ... a boutique public relations firm outside of Philadelphia, have offered these three tips to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... skincare products, was awarded as winners of American Dreams & Good Housekeeping Seal ... hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ., ...
(Date:3/23/2017)... , ... March 23, 2017 , ... News Advisory/Interview Opportunity ... has helped score a major victory in Europe for public health and the environment ... , Based on rigorous scientific research and the overwhelming support of European citizens, the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: